A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
NovoCure Ltd operates in the Surgical & Medical Instruments & Apparatus industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 655M | 655M | 605M | 509M | 538M | 535M |
| Net Income | -136M | -136M | -169M | -207M | -93M | -58M |
| EPS | $-1.22 | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
| Free Cash Flow | -76M | -76M | -69M | -100M | 9.4M | 59M |
| ROIC | -25.1% | -27.4% | -36.9% | -22.2% | -9.2% | -6.0% |
| Gross Margin | 74.5% | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% |
| Debt/Equity | 0.70 | 0.70 | 3.42 | 1.64 | 1.32 | 1.40 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -154M | -154M | -170M | -233M | -90M | -44M |
| Operating Margin | -23.5% | -23.5% | -28.2% | -45.7% | -16.6% | -8.3% |
| ROE | -40.0% | -38.9% | -46.8% | -57.1% | -21.0% | -14.2% |
| Shares Outstanding | 112M | 112M | 108M | 106M | 105M | 104M |
NovoCure Ltd passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 76.8%. At current prices, the estimated annualized return to fair value is +30.7%.
NovoCure Ltd (NVCR) has a 5-year average return on invested capital (ROIC) of -20.3%. This is below average and may indicate limited pricing power.
NovoCure Ltd (NVCR) has a market capitalization of $1.2B. It is classified as a small-cap stock.
NovoCure Ltd (NVCR) does not currently pay a regular dividend.
NovoCure Ltd (NVCR) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
NovoCure Ltd (NVCR) reported annual revenue of $655 million in its most recent fiscal year, based on SEC EDGAR filings.
NovoCure Ltd (NVCR) has a net profit margin of -20.8%. The company is currently unprofitable.
NovoCure Ltd (NVCR) generated $-76 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NovoCure Ltd (NVCR) has a debt-to-equity ratio of 0.70. This indicates moderate leverage.
NovoCure Ltd (NVCR) reported earnings per share (EPS) of $-1.22 in its most recent fiscal year.
NovoCure Ltd (NVCR) has a return on equity (ROE) of -38.9%. A negative ROE may indicate losses or negative equity.
NovoCure Ltd (NVCR) has a 5-year average gross margin of 76.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for NovoCure Ltd (NVCR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NovoCure Ltd (NVCR) has a book value per share of $3.05, based on its most recent annual SEC filing.